10-Q: Aethlon Medical Narrows Losses, Advances Hemopurifier Trial

Aethlon Medical reported reduced net losses and advanced its Hemopurifier oncology trial in Australia, while addressing Nasdaq listing compliance and acknowledging ongoing capital needs.

Summary

• Net loss for the six months ended September 30, 2025, significantly decreased to $3,248,958 from $5,378,414 in the prior year period.
• Operating expenses for the six months ended September 30, 2025, decreased by 40% to $3,302,220 compared to $5,521,856 in the same period of 2024, primarily due to reduced payroll and general and administrative expenses.
• Cash and cash equivalents increased to $5,853,493 as of September 30, 2025, from $5,501,261 at March 31, 2025.
• Working capital improved to $4,848,883 at September 30, 2025, from $4,050,514 at March 31, 2025.
• The company completed a registered direct offering on September 5, 2025, raising approximately $3.7 million in net proceeds.
• Enrollment for Cohort 2 of the Phase 1 oncology trial in Australia is now open, following a positive safety review of Cohort 1 by the Data Safety Monitoring Board (DSMB).
• The planned oncology clinical trial in India was cancelled to conserve resources and focus on the Australian trial due to extended timelines.
• The company implemented a 1-for-10 reverse stock split on October 16, 2025, and a 1-for-8 reverse stock split on June 9, 2025, to maintain Nasdaq listing compliance.
• Aethlon regained compliance with Nasdaq's minimum bid price requirement on October 31, 2025, with Nasdaq closing the matter on November 5, 2025.
• Pre-clinical research demonstrated over 98% removal of platelet-derived extracellular vesicles (EVs) by the Hemopurifier in a simulated clinical session, and data supporting its potential utility in Long COVID patients was presented.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company successfully reduced losses, advanced its clinical trial, and resolved a Nasdaq compliance issue, the explicit 'going concern' warning and continuous need for capital remain significant concerns. The cancellation of the India trial, while strategic, also represents a setback in broader development plans. The positive clinical safety data and pre-clinical findings are encouraging but are overshadowed by the fundamental financial instability.

Positives

• Net loss significantly reduced by 39.5% for the six months ended September 30, 2025, to $3.25 million from $5.38 million in the prior year.
• Operating expenses decreased by 40% for the six months ended September 30, 2025, reflecting effective cost management, including reduced payroll and general and administrative costs.
• Cash and cash equivalents increased to $5.85 million, and working capital improved to $4.85 million as of September 30, 2025.
• The Phase 1 oncology trial in Australia is progressing, with Cohort 1 demonstrating a favorable safety and tolerability profile and no serious adverse events or dose-limiting toxicities reported.
• Enrollment for Cohort 2 of the Australian oncology trial is now open, indicating continued clinical advancement.
• Successful completion of a registered direct offering generated $3.7 million in net proceeds, bolstering the company's cash position.
• Regained compliance with Nasdaq's minimum bid price requirement, resolving a significant listing concern.
• Pre-clinical studies continue to show promise, with the Hemopurifier demonstrating >98% removal of platelet-derived extracellular vesicles and potential utility in Long COVID patients.

Negatives

• Management expects existing cash as of September 30, 2025, to not be sufficient to fund operations for at least twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• The planned oncology clinical trial in India was cancelled due to extended timelines and a strategic decision to conserve resources, limiting potential geographic expansion.
• The company incurred two reverse stock splits (1-for-8 in June 2025 and 1-for-10 in October 2025) within a short period to maintain Nasdaq listing, indicating prior share price weakness.
• Net cash provided by financing activities decreased by approximately $1.64 million for the six months ended September 30, 2025, compared to the prior year, despite the recent offering.
• The company continues to incur significant net losses and negative cash flows from operating activities, with no commercial revenue generated.

Risks

• Incurred significant losses and expects to continue incurring losses for the foreseeable future.
• Requires additional financing to sustain operations, achieve business objectives, and satisfy cash obligations, which may dilute existing stockholders.
• Limited experience in identifying and working with large-scale contracts with medical device manufacturers; device manufacturing must comply with good manufacturing practices.
• Delays, interruptions, or cessation of production by third-party suppliers or delays in qualifying new materials may prevent or delay Hemopurifier manufacturing.
• Hemopurifier technology may become obsolete.
• Failure to comply with extensive regulations of U.S. and foreign regulatory agencies could delay or prevent product commercialization.
• Difficulty attracting and retaining executive management and directors as a public company with limited financial resources undertaking new medical technologies.
• Expansion of operations may strain resources; inability to manage growth could delay or derail business objectives.
• Success is dependent in part on executive officers.
• Delays in successfully commencing or completing planned clinical trials could jeopardize regulatory approval and ability to sustain operations.
• Inadequate funding for the FDA, other government agencies, or comparable foreign regulatory authorities could hinder their ability to perform normal business functions, impacting business operations and regulatory review timelines.
• Impact of inflation, recent bank failures, and geopolitical conflicts (Russia-Ukraine, Israel) on capital markets, U.S. economy, and access to capital is uncertain.

Future Outlook

Management expects to continue incurring increasing negative cash flows and net losses for the foreseeable future. Future capital requirements are dependent on clinical trial progress, intellectual property protection, regulatory approvals, competitive landscape, and strategic partnerships. The company plans to access equity markets for additional capital, but there is no assurance of favorable terms or availability. The impact of global economic conditions, bank failures, inflation, and geopolitical conflicts on timelines and future access to capital remains uncertain.

Management Comments

• We are actively evaluating a range of strategic and financing options to extend our cash runway and support our ongoing operations, including clinical development activities.
• There can be no assurance that any such financing will be available on acceptable terms, or at all.
• If we are unable to raise additional capital when needed, we may be forced to significantly curtail or cease operations, including research and development programs and clinical trials.
• The Hemopurifier continues to demonstrate a favorable safety and tolerability profile, with no serious adverse events or dose-limiting toxicities reported to date in the Australian oncology trial.
• The decision to cancel the Indian trial enables the Company to focus its resources on advancing its ongoing clinical trial in Australia, which remains more closely aligned with its objective of generating timely clinical data.
• We maintain an open IDE for viral indications, preserving the ability to respond to future outbreaks or emerging pathogens.
• We have sufficient inventory of Hemopurifiers to support our ongoing oncology trial in Australia as well as any near-term expansion of that study or potential trial activity in India.
• We believe that certain patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.

Industry Context

Aethlon Medical operates in the highly competitive and capital-intensive medical therapeutic device industry, specifically targeting oncology and infectious diseases with its Hemopurifier. The Breakthrough Device designation from the FDA provides a potential expedited pathway, which is crucial in an industry with long development cycles and high regulatory hurdles. The focus on extracellular vesicles (EVs) aligns with emerging research in cancer and autoimmune diseases. The termination of COVID-19 trials due to low enrollment reflects the dynamic nature of infectious disease outbreaks and the challenges of clinical trial recruitment. The company's reliance on external financing and the 'going concern' warning are common for development-stage biotech firms, highlighting the significant financial risks inherent in bringing novel medical technologies to market.

Comparison to Industry Standards

• NA As a development-stage company without commercial revenue, direct comparisons to industry-standard profitability or revenue benchmarks are not applicable. The focus is on clinical progress and cash burn.
• The Breakthrough Device designation for the Hemopurifier is a significant achievement, placing it among a select group of innovative medical technologies recognized by the FDA for potentially providing more effective treatment for life-threatening conditions where no approved therapies exist. This designation is comparable to those received by other leading biotech firms developing novel therapies for unmet medical needs.
• The safety profile observed in Cohort 1 of the Australian oncology trial (no SAEs or DLTs) is a positive indicator, aligning with early-stage clinical trial objectives for novel devices, similar to initial safety data reported by other companies in Phase 1 oncology studies.
• The company's cash runway of less than 12 months and 'going concern' warning are common for early-stage biotech companies, particularly those in clinical development, and are comparable to the financial challenges faced by many small-cap biopharmaceutical firms that rely heavily on capital raises to fund R&D.

Corporate Governance

Legal Proceedings

• Not presently a party to any pending or threatened legal proceedings.

Related Party Transactions

• Accrued $68,250 for board fees and paid $68,250 to non-employee directors during the three months ended September 30, 2025.
• Accrued $136,500 for board fees and paid $136,500 during the six months ended September 30, 2025 and 2024.
• Accrued separation expenses of $17,451 at September 30, 2025, related to an agreement with a former executive officer from a prior period.

Stakeholder Impact

• Shareholders: Experienced significant dilution from recent capital raise and reverse stock splits. Face substantial risk due to the 'going concern' warning and ongoing need for financing. Potential upside if clinical trials are successful and regulatory approvals are obtained.
• Employees: Reduced headcount and lower compensation costs were noted, indicating potential job insecurity. Stock-based compensation is part of their remuneration.
• Customers (future): Potential for new therapeutic options in cancer and viral infections if the Hemopurifier successfully completes trials and gains regulatory approval.
• Creditors: The company's liquidity and 'going concern' status present elevated risk for creditors, although restricted cash supports lease obligations.
• Regulatory Authorities: Continued engagement with FDA for manufacturing approvals and ongoing clinical trial oversight in Australia.

Next Steps

• Enrollment for Cohort 2 of the Phase 1 oncology trial in Australia is open, with participants receiving two Hemopurifier treatments over a one-week period.
• Continue to explore potential new applications for the Hemopurifier through internal pre-clinical research and academic collaborations.
• Seek FDA approval for a separate supplement to qualify an additional supplier of a key Hemopurifier component.
• Actively evaluate a range of strategic and financing options, including potential equity offerings, to extend the cash runway and support ongoing operations.
• Monitor the impact of inflation, bank failures, and geopolitical conflicts on business, financial condition, clinical trials, and access to capital.

Key Dates

Recommendation

While Aethlon Medical has shown progress in reducing its net losses and advancing its key clinical trial in Australia with positive safety data, the explicit 'going concern' warning and the continuous need for significant capital raises present substantial risks. The recent capital raise and Nasdaq compliance resolution provide temporary stability but do not fundamentally alter the long-term financial challenges of a development-stage biotech. The cancellation of the India trial, while a resource-saving measure, also indicates a narrowing of immediate strategic options. Given the high-risk, high-reward nature of clinical-stage biotechnology, coupled with the severe liquidity concerns, a 'hold' recommendation is appropriate for existing investors who are aware of the risks and believe in the long-term potential of the Hemopurifier. New investors should exercise extreme caution due to the significant financial uncertainties.

Keywords

Hemopurifier, oncology trial, viral infections, extracellular vesicles, Breakthrough Device, medical device, clinical-stage, biotechnology, Nasdaq compliance, reverse stock split, capital raise, going concern, FDA approval, immunotherapeutic